Regeneron Pharmaceuticals (NASDAQ:REGN) saw its stock rise 2% after announcing it had secured a winning bid to acquire key assets of genetic testing company 23andMe through a bankruptcy auction. The $256 million deal is poised to significantly enhance Regeneron’s capabilities in genetics-driven research and drug development.

Regeneron (REGN) wins $400M in damages as jury finds Amgen (AMGN) violated antitrust laws by promoting its heart drug Repatha over rival's Praluent. Read more here.

In children aged 8 to 11 years, PRALUENT should be given by a caregiver. Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming ...

The market’s positive reaction to OraSure’s stock today reflects investor confidence in the company’s ongoing relationship with 23andMe under Regeneron’s ownership. The continuation of this relationship is seen as a positive development for OraSure’s revenue prospects.

The planned purchase will allow Regeneron to integrate 23andMe’s extensive genetic data into its research efforts, potentially leading to new medical advancements. Regeneron has stated its commitment to maintaining the privacy and security of 23andMe’s customer data,

There are 2,406 funds or institutions reporting positions in Regeneron Pharmaceuticals ... author and do not necessarily reflect those of Nasdaq, Inc. Fintel is a leading provider of financial ...

The most significant addition was Regeneron Pharmaceuticals Inc (NASDAQ:REGN), with 114,880 shares, accounting for 3.88% of the portfolio and a total value of $72,860,340 million. The second largest addition to the portfolio was Tripadvisor Inc (NASDAQ:TRIP),